Skip to main content

Table 3 Subgroup analysis of the HBV pooled prevalence estimation in East Africa from 2005 to 2020

From: Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020

Sub-groups

 

Analysis of HBV prevalence

Analysis of heterogeneity

 

Variable

Category

No

Prevalence %(95%CI)

P value

I2% (95%CI)

P het

Model

 

Kenya

6

8.54 (5.09 to 12.76) Ref

 

92.36 (86.11 to 95.79)

< 0.0001

Random

Country

Uganda

9

8.454 (5.76 to 11.73)

0.9637

97.28 (96.15 to 98.08)

< 0.0001

Random

 

Rwanda

7

4.06 (3.80 to 4.34)

< 0.0001*

85.39 (71.83 to 92.42)

< 0.0001

Random

 

Tanzania

13

5.16 (4.24 to 6.17)

0.0006*

80.65 (67.84 to 88.35)

< 0.0001

Random

Year of Publication

2011–2015

10

8.759 (6.09 to 11.85) Ref

 

95.65 (93.65 to 97.2)

< 0.0001

Random

 

2005–2010

8

6.95 (5.11 to 9.05)

0.1208

87.4 (77.34 to 92.98)

< 0.0001

Random

 

2016–2020

19

4.388 (3.901 to 4.903)

< 0.0001*

96.17 (95.04 to 97.04)

< 0.0001

Random

Sampling Technique

Probability

11

7.799 (5.182 to 10.897)

 

98.45 (97.99 to 98.80)

< 0.0001

Random

 

Non-probability

26

5.361 (4.567 to 6.215)

< 0.0001*

96.91 (96.21 to 96.49)

< 0.0001

Random

Diagnostic Technique

ELISA

14

5.214 (4.71 to 5.74) Ref

 

90.48 (85.79 to 93.62)

< 0.0001

Random

 

RDT

15

6.638 (4.997 to 8.493)

0.0126*

94.18 (91.88 to 95.83)

< 0.0001

Random

 

EIA

4

6.127 (1.259 to 14.303)

0.2349

99.62 (99.50 to 99.72)

< 0.0001

Random

 

Others

4

3.924 (3.697 to 4.16)

0.0622

22.55 (0.00 to 90.00)

0.257

Fixed

  1. ELISA Enzyme Linked Immunosorbent Assay, RDT Rapid Diagnostic Test, EIA Enzyme Immunoassay
  2. *P value of sub group prevalence with respect to the group reference (where applicable) < 0.05 statistically significant